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Aim: Spectrum of acute coronary syndrome (ACS) has not been reported from North Eastern
India. The present study was undertaken to study the clinical spectrum of ACS.
Methods: We prospectively collected data of 704 ACS patients from February 2011 to August
2012 in Gauhati Medical College, a tertiary care center. We evaluated data on clinical
characteristic, treatment, and outcome in ACS patients.
Results: Of the 704 ACS patients, 72.4% presented with STEMI and 27.6% presented with
NSTEMI/UA. Mean age of presentation was 56.5 years. Mean time to presentation was 11.42 h
and was higher in NSTEMI/UA than STEMI (12.86 h vs. 9.98 h, p < 0.001). Treatment for STEMI
did not differ much from NSTEMI/UA with ≥90% of patients in both groups receiving
antiplatelets, statin, and anticoagulants. 39% of STEMI received thrombolytic therapy and
percutaneous coronary intervention (PCI) rates were higher in STEMI. The 30-day mortality
was found to be 10.22%, with STEMI having higher mortality than NSTEM/UA (11.76% vs.
6.18%, p = 0.03).
Conclusion: These data represent the ﬁrst reported study on spectrum of ACS in North
Eastern India and has noted few key differences from the national registry CREATE, with
greater percentage of STEMI patients, greater delay in seeking treatment, greater 30-day
mortality, and lesser percentage of patients receiving reperfusion therapy.
# 2015 Cardiological Society of India. Published by Elsevier B.V. All rights reserved.
Available online at www.sciencedirect.com
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CREATE, the national registry on Indian patients with ACS, has
shown that the pattern of ACS among Indians is much
different from that of the Western populations [1].* Corresponding author.
E-mail addresses: farhiniqbal@rediffmail.com, farhiniqbal@gmail.c
http://dx.doi.org/10.1016/j.ihj.2015.07.040
0019-4832/# 2015 Cardiological Society of India. Published by ElsevieThe clinical spectrum of ACS is not studied in North Eastern
India.
The present study was undertaken in Gauhati
Medical College, a tertiary care hospital with the aim of
studying the clinical presentation of the wide spectrum
of ACS.om (F. Iqbal).
r B.V. All rights reserved.
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All patients presenting with ACS from February 2011 to August
2012 in the emergency room (ER) were included in the study.
Detailed history, physical examination, and necessary inves-
tigations were done in all patients.
Inclusion criteria
1. Patients must be greater than 18 years of age.
2. Patients must fulﬁll the diagnostic criteria of ACS as given
below:
Diagnosis of myocardial infarction was made if there is:
Typical rise and gradual fall (troponin) or more rapid rise and
fall (CK-MB) of biochemical markers of myocardial necrosis
with at least one of the following: [2]
(a) Ischemic symptoms;
(b) Development of pathologic Q waves on the ECG;
(c) ECG changes indicative of ischemia (ST segment elevation
or depression).
Cases of ischemic symptoms with elevation of ST segment
in electrocardiographic (ECG) leads/presumed new onset left
bundle branch block in ECG were categorized as STEMI. Cases
of ischemic symptoms without ST segment elevation were
categorized as NSTEMI if their cardiac biomarkers are positive.
Unstable Angina (UA) was deﬁned as angina pectoris (or
equivalent type of ischemic discomfort) with at least one of
three features:
(1) occurring at rest (or minimal exertion) and usually lasting
>20 min (if not interrupted by nitroglycerin administra-
tion);
(2) being severe and described as frank pain, and of new onset
(i.e., within 1 month; and
(3) occurring with a crescendo pattern (i.e., more severe,
prolonged, or frequent than previously).
(4) Patients with above features without elevation in cardiac
markers were categorized as UA) [3].
3. Written consent must be given
Exclusion criteria
1. Patients who were initially treated elsewhere and referred
to the study center only for additional management;
2. Patients with proven non-cardiac chest pain and
3. Patients who were discharged before completion of the
treatment for any reasons.
The baseline clinical characteristics, which were analyzed,
were the age, gender, hypertension, diabetes mellitus, smok-
ing status, and Body mass Index (BMI).
Mode of presentation, time of occurrence of the ACS,
clinical course in the hospital, time to reach hospital, time
until thrombolysis, treatments in hospital, the mean duration
of hospital stay, and complications related to the ACS and itstreatment were analyzed. In our study, patients were consid-
ered to have atypical presentation if they presented with
dyspnea, nausea/vomiting, indigestion, fatigue, sweating, and
arm or shoulder pain as presenting symptoms in the absence
of chest pain.
The in-hospital outcome was analyzed. Those patients
giving consent for angiography were taken up for angiography.
Angiographic ﬁndings were noted. They were categorized as -
1, Normal coronaries; 2, insigniﬁcant disease (less than 50%
diameter stenosis as per visual estimation); 3, single vessel
disease; 4, double vessel disease; 5, triple vessel disease; 6, left
main disease.
A comparison of clinical parameters, treatment received in
hospital and outcome and angiographic proﬁle between STEMI
and NSTEMI/UA were done.
The authors certify that informed consent has been
obtained from each patient and the study protocol conforms
to the ethical guidelines as approved by the institution's
human ethics committee.
3. Statistical methods
Statistical analysis was performed using the online statistical
calculator, www.graphpad.com/.
Categorical variables were compared by chi-square test and
the continuous variables are presented as mean (SD) and
were compared by unpaired t test. A probability value of <0.05
was considered statistically signiﬁcant.
4. Results
A total of 704 consecutive cases of ACS were included in the
present study. Out of 704 patients, 510 (72.4%) presented with
STEMI and 194 (27.6%) presented with NSTEMI/UA. Of the 194
patients with NSTEMI/UA, 121 (62.37%) presented with NSTEMI
and 73 (37.6%) presented with UA. Males outnumbered females
in STEMI, but in NSTEMI/UA, both the sexes were almost equal.
Mean age of presentation was 56.5 years. The mean age of
NSTEMI/UA is higher than STEMI patients (57.2 years vs. 55.8
years, p = 0.05).
Mean time to presentation was 11.42 h and was higher in
NSTEMI/UA than STEMI (12.86 h vs 9.98 h, p < 0.001). 45.02%
were smokers, 43.75% were hypertensive, 36.36% were diabetic,
and 27.98% had BMI ≥ 25. 24.5% of ACS presented with atypical
presentation. We observed that patients with NSTEMI/UA have
higher incidence of atypical presentation, higher incidence of
diabetes, hypertension and high BMI, and higher mean time to
presentation than STEMI (Ref Table 1).
On observing the treatment pattern, we observed that there
was not much of a difference in treatment pattern between
STEMI and NSTEMI/UA with high percentage in both groups of
patients receiving standard medical therapy (Ref Table 1).
However in STEMI, of the 510 patients, 39% patients received
thrombolysis. Except 1 patient, all received streptokinase. The
mean door to needle time was 30.12 min. The reasons for not
administering thrombolytic therapy were the late presenta-
tion of cases in 281 (55.09%) patients, non-satisfactory ECG
criteria in 12 (2.35%), and contra-indications for thrombolysis
Table 1 – Clinical characteristic, treatment and outcome in ACS.
ACS Total STEMI NSTEMI/UA p value
N 704 510 194 <0.001
Clinical characteristic
Mean age 56.5 years 55.8 years 57.2 years 0.05
Sex (male) 436(61.93%) 336(65.8%) 100(51.5%) 0.007
Smoker 317(45.02%) 235(46.07%) 82(42.2%) 0.4
Hypertension 308(43.75%) 210(41.1%) 98(50.5%) 0.02
Diabetes 252(36.36%) 174(34.1%) 78(42.2%) 0.04
BMI ≥ 25 197(27.98%) 135(26.4%) 62(31.9%) 0.03
Mean time to presentation 11.42 h 9.98 h 12.86 h <0.001
Atypical presentation 172(24.5%) 102(20%) 70(36.09%) <0.001
Mean EF% 47.06% 46.34% 48.6% 0.13
Treatment in hospital
Aspirin 699(99.2%) 506(99.2%) 193(99.4%) 0.70
Clopidogrel 695(98.7%) 502(98.4%) 193(99.4%) 0.46
Statins 699(99.2%) 506(99.2%) 193(99.4%) 0.70
ACEI/ARB 641(91.05%) 459(90%) 182(93.8%) 0.1
Beta blockers 633(89.9%) 456(89.4%) 177(91.23%) 0.56
LMWH 687(97.5%) 496(97.2%) 191(98.4%) 0.51
Thrombolysis 205(29.11%) 199(39%) 5(2.5%) <0.001
PCI 90(12.78%) 75(14.7%) 15(7.7%) 0.01
Outcome at 30 days
Heart failure/cardiogenic shock 87(12.3%) 65(12.7%) 22(11.3%) 0.7
Reinfarction 38(5.39%) 34(6.66%) 4(2.06%) 0.01
Cardiac arrest (resuscitated) 38(5.39%) 33(6.47%) 5(2.57%) 0.04
Stroke 3(0.4%) 3(0.58%) 0% 0.5
Death 72(10.22%) 60(11.76%) 12(6.18%) 0.03
Cause of death
Pump failure 35(48.6%) 27(45%) 8(66.6%) 0.69
Asystole 10(13.8%) 10(18.51%) 0 0.06
VF 12(16.6%) 10(18.51%) 2(16.6%) 0.5
Multifactorial 15(20.83%) 13(24%) 2(16.6%) 0.25
Table 2 – Coronary angiography in ACS.
ACS Total STEMI NSTEMI/
UA
p value
N(%) 326(46.30%) 244(47.84%) 82(42.26%) 0.21
Normal 28(8.58%) 10(4.09%) 18(21.95%) <0.001
Insigniﬁcant
CAD
18(5.52%) 11(4.5%) 7(8.53%) 0.27
SVD 183(56.13%) 154(63.31%) 29(35.36%) <0.001
DVD 61(18.71%) 49(20.08%) 12(14.63%) 0.35
TVD 21(8.28%) 14(5.73%) 13(16.6%) 0.008
Left main 9(2.76%) 6(2.45%) 3(3.65%) 0.85
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than NSTEMI/UA (14.7% vs. 7.7%, p = 0.01). However, only 1.76%
of STEMI underwent primary PCI.
The mean hospital day is 4.98  1.41 days. The mean
hospital days in STEMI is 5  1.43, whereas in NSTEMI/UA it is
4.92  1.37. There is no statistical signiﬁcant difference in
hospital days between STEMI and NSTEMI/UA.
The 30-day mortality was found to be 10.22%. Patients with
STEMI had signiﬁcantly higher mortality than NSTEM/UA
(11.76% vs 6.18%, p = 0.03). The most common cause of
death is pump failure (48.6%). Out of 72 deaths, 67 occurred
during index hospitalization and 5 died after being discharged
(Ref. Table 1).
Coronary angiography was obtained in 46.30% and
Echocardiography was obtained in 97.1% of ACS patients.
We observed that STEMI patients have marginally lower
ejection fraction and signiﬁcant increase in incidence of
single vessel disease than NSTEMI/UA, whereas NSTEMI/UA
patients have greater increase in incidence of normal
coronaries and also greater increase in triple vessel disease
(Ref. Table 2).
5. Discussion
This is the ﬁrst reported study on ACS from North Eastern
India.In our study, majority of ACS patients presented with
STEMI. This is in contrast to Western studies, where Non-
STEMI predominates in ACS [4–6]. However, predominance
of STEMI patients in ACS in our study is comparable to
Indian studies, which has also shown predominance of STEMI
in ACS [1,7,8].
In our study, the mean age at presentation of ACS cases was
56.5 years, which is a decade earlier than western studies [4–6]
and is comparable with mean age of cases from the Indian
studies [1,7,8].
While analyzing the clinical characteristic between STEMI
Diff id="80">[80_TD$DIFF]and NSTEMI/UA we observed that
patients with NSTEMI/UA have higher incidence of atypical
presentation, higher incidence of diabetes, hypertension and
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Similar observation has been made in various global registry
and national registry [1,4–6].
In our study, of the 510 patients with STEMI, 39% patients
received thrombolysis and 1.76% patients received Primary
PCI. Very low proportions of STEMI cases in our study, when
compared to other Indian studies, received reperfusion
therapy [1,7,8]. Various factors could be responsible for high
incidence of non-thrombolysis in our study. One of the main
reasons is delayed presentation, which could be related to
economic reasons, a lack of awareness of the importance
of the symptoms, lack of ambulance services, and trafﬁc
congestion in the roads. In our study, only 1.76% patients
received Primary PCI. The reason for low percentage of Primary
PCI is that our center has very recently started Catheterization
Laboratory, and we do not have dedicated technical staff for
attending patients at night. Moreover, most of our patients are
poor and cannot afford Primary PCI.
In our study, 30-day mortality was found to be 10.22%.
Patients with STEMI had signiﬁcantly higher mortality than
NSTEM/UA (11.76% vs 6.18%, p = 0.03). The 30-day and in-
hospital mortality is signiﬁcantly higher compared to other
studies, however similar to our study mortality in STEMI has
been found to be higher compared to NSTEMI/UA in other
studies [1,4–8].
On angiography, in STEMI, single vessel disease was the
commonest pattern with 63.31% of patients having single
vessel disease. Studies studying the pattern of CAD on
angiography in STEMI have observed high incidence of Multi
vessel disease in the range of 41–67% depending upon the
baseline characteristics of the speciﬁc population studied
[9,10]. In our study, in NSTEMI/UA, normal coronaries were
found in 21.95%, insigniﬁcant CAD was observed in 8.53%, SVD
in 35.36%, DVD in 14.63%, TVD in 16.6%, and left main disease
in 3.65%. Contrary to our study, lesser incidence of normal
coronaries and higher incidence of multivessel disease has
been observed in TACTICS-TIMI 18 study [11].
6. Study limitation
There are certain limitations of our study. First, this is a single
center study and pattern of ACS can be different in other parts of
state. Second, coronary angiography was obtained in only
46.30% patients (who gave consent), so actual value could have
been different, had we got all patients for coronary angiography.
7. Conclusion
These data represent the ﬁrst reported study on spectrum of
ACS in North Eastern India and has noted few key differences
from national registry, CREATE with greater percentage of
STEMI patients, greater delay in seeking treatment, greater 30-
day mortality, and lesser percentage of patients receiving
reperfusion therapy.Conﬂicts of interest
The authors have none to declare.
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